‘Strategic’ development of precision cancer medicine in the United States

The availability of advanced omics technologies has largely driven development of precision cancer medicine in the United States, but integration in routine cancer care has been challenging. Here, we consider some parameters that would enable a more coordinated, integrated, efficient, and equitable...

Descripción completa

Detalles Bibliográficos
Autor principal: Schilsky, Richard L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253098/
https://www.ncbi.nlm.nih.gov/pubmed/34053185
http://dx.doi.org/10.1002/1878-0261.13023
_version_ 1783717440181501952
author Schilsky, Richard L.
author_facet Schilsky, Richard L.
author_sort Schilsky, Richard L.
collection PubMed
description The availability of advanced omics technologies has largely driven development of precision cancer medicine in the United States, but integration in routine cancer care has been challenging. Here, we consider some parameters that would enable a more coordinated, integrated, efficient, and equitable implementation of precision cancer medicine.[Image: see text]
format Online
Article
Text
id pubmed-8253098
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82530982021-07-13 ‘Strategic’ development of precision cancer medicine in the United States Schilsky, Richard L. Mol Oncol Viewpoint The availability of advanced omics technologies has largely driven development of precision cancer medicine in the United States, but integration in routine cancer care has been challenging. Here, we consider some parameters that would enable a more coordinated, integrated, efficient, and equitable implementation of precision cancer medicine.[Image: see text] John Wiley and Sons Inc. 2021-06-24 2021-07 /pmc/articles/PMC8253098/ /pubmed/34053185 http://dx.doi.org/10.1002/1878-0261.13023 Text en © 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Viewpoint
Schilsky, Richard L.
‘Strategic’ development of precision cancer medicine in the United States
title ‘Strategic’ development of precision cancer medicine in the United States
title_full ‘Strategic’ development of precision cancer medicine in the United States
title_fullStr ‘Strategic’ development of precision cancer medicine in the United States
title_full_unstemmed ‘Strategic’ development of precision cancer medicine in the United States
title_short ‘Strategic’ development of precision cancer medicine in the United States
title_sort ‘strategic’ development of precision cancer medicine in the united states
topic Viewpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253098/
https://www.ncbi.nlm.nih.gov/pubmed/34053185
http://dx.doi.org/10.1002/1878-0261.13023
work_keys_str_mv AT schilskyrichardl strategicdevelopmentofprecisioncancermedicineintheunitedstates

Ejemplares similares